Sandra Turner

Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial

James W. Denham, Allison Steigler, David S. Lamb et al. · The Lancet Oncology · 2011 · 445 citations

Medicine, Oncology, Urology +16

Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial

James W. Denham, Allison Steigler, David S. Lamb et al. · The Lancet Oncology · 2005 · 377 citations

Medicine, Oncology, Radiation Oncology +15

Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial

Andrew Kneebone, Carol Fraser‐Browne, Gillian Duchesne et al. · The Lancet Oncology · 2020 · 363 citations · Full text

Medicine, Surgery, Urology +13

Prognostic factors for favorable outcome in disseminated germ cell tumors.

Robert Birch, Stephen D. Williams, A. J. Cone et al. · Journal of Clinical Oncology · 1986 · 295 citations

Medicine, Oncology, Surgery +17

Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial

Gillian Duchesne, Henry H. Woo, Julie K. Bassett et al. · The Lancet Oncology · 2016 · 217 citations · Full text

Medicine, Oncology, Urology +16